Sign Up
Stories
BioCorRx Appoints Neuroscientist to Board
Share
Controlled Substance Market Projections
Growing Markets for Pain Relief
Innovative Pancreatic Cancer Test Advanc...
ARCpoint Inc. Conference Call Update
Ibogaine: A Holistic Health Solution
Minerva Neurosciences Advances CNS Thera...
Overview
API
BioCorRx Pharmaceuticals appoints neuroscientist Dr. Kate Beebe DeVarney to its Board of Directors to advance BICX104, a drug for opioid use disorder treatment.
Ask a question
How does the appointment of a neuroscientist reflect BioCorRx's commitment to addressing the complex challenges of substance abuse?
How might Dr. DeVarney's appointment impact the development and success of BICX104?
What are the potential implications of BioCorRx's collaboration with NIDA in the field of substance abuse treatment?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage